Company intelligence / Profile preview

MediMabBio

Seongnam-si/Sujeong-gu, Gyeonggi-do, South Koreamedimabbio.com ↗

Ownership: Private
Employees: ~17
Development stage: Preclinical

Overview

MediMabBio is developing novel antibody-based immunotherapies for cancer, using proprietary platforms that combine systems biology with sophisticated immune engineering. The company has established global academic collaborations and R&D partnerships to accelerate its pipeline. It has received recognition for innovation, workspace excellence, and young talent employment in South Korea. Clinical results are not yet publicly available as programs are preclinical/early stage.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)Cytokine-fusion antibodiesProtein-based therapeutics
Industry: Biotech

Drug pipeline

5 assets

MFA 031

Preclinical

4 more assets in the full pipeline.

Partnerships

CelltrionPDC*line PharmaPatheonCharles River LaboratoriesUniversity of OxfordUniversity of BirminghamKAISTAsan Foundation Hospital/Bio Escalator UK

Beyond the preview

Go deeper on MediMabBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MediMabBio.